Reuters logo
BRIEF-Abeona Therapeutics receives orphan drug designation in the EU for ABO-201 gene therapy program
January 3, 2017 / 1:02 PM / 9 months ago

BRIEF-Abeona Therapeutics receives orphan drug designation in the EU for ABO-201 gene therapy program

Jan 3 (Reuters) - Abeona Therapeutics Inc :

* Abeona Therapeutics receives orphan drug designation in the European Union for ABO-201 gene therapy program in juvenile batten disease

* Abeona Therapeutics Inc - “This designation helps advance ABO-201 program and we look forward to initiating human clinical trials later this year” Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below